Revance Therapeutics (RVNC) Sees Strong Upside on Volume

September 16, 2016 11:57 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Revance Therapeutics (NASDAQ: RVNC) is seeing notable upside Friday. Shares are up 18% on volume that is running 10x normal. It is unclear today's driver.

Analyst Louise Chen at Guggenheim recently noted upcoming potential catalysts include: 1) 2H16 - Report top-line data for RT002 in Cervical Dystonia; 2) 2H16 - Initiate Phase 3 program for RT002 for Glabellar Lines; 3) 2H16 - Announce an additional indication for RT002; 4) '17 - RT002, Phase 3 data for Glabellar Lines; 5) '17 - More data on Cervical Dystonia and additional indication; 6) '20 - RT002, Approval and Launch for Glabellar Lines; and 7) '22/'23 - RT002, Cervical Dystonia.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Related Entities

Louise Chen, Guggenheim

Add Your Comment